GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » Cash And Cash Equivalents

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Cash And Cash Equivalents : HK$1,237 Mil (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) Cash And Cash Equivalents?

Dawnrays Pharmaceutical (Holdings)'s quarterly cash and cash equivalents increased from Dec. 2023 (HK$990.77 Mil) to Jun. 2024 (HK$1,218.99 Mil) and increased from Jun. 2024 (HK$1,218.99 Mil) to Dec. 2024 (HK$1,236.64 Mil).

Dawnrays Pharmaceutical (Holdings)'s annual cash and cash equivalents increased from Dec. 2022 (HK$906.42 Mil) to Dec. 2023 (HK$990.77 Mil) and increased from Dec. 2023 (HK$990.77 Mil) to Dec. 2024 (HK$1,236.64 Mil).


Dawnrays Pharmaceutical (Holdings) Cash And Cash Equivalents Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) Cash And Cash Equivalents Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 866.54 707.43 906.42 990.77 1,236.64

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 906.42 810.65 990.77 1,218.99 1,236.64

Dawnrays Pharmaceutical (Holdings) Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Dawnrays Pharmaceutical (Holdings) Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Li Kei Ling
Hung Yung Lai
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Li Tung Ming
Fmr Llc 2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines